CGT

102개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved102 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleAstraZenecaPhase 2

autologous CD19-directed chimeric antigen receptor (CAR, autologous CD19-directed chimeric antigen receptor, autologous CD19-directed chimeric antigen receptor (CAR) T-cells)

Relapsed Non Hodgkin Lymphoma; Relapsed Adult ALL · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 154Status Recruiting
CGTLimited DatastaleShanghai Ming Ju Biotechnology …Phase 2

CD19-targeted Chimeric Antigen Receptor (CAR, CD19-targeted Chimeric Antigen Receptor, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells)

Lymphoma, Non-Hodgkin; Diffuse Large B Cell Lymphoma · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 64Status Active
CGTLimited DatastaleAbClonPhase 2

Anti-CD19 Chimeric Antigen Receptor T cell (AT101, AT101(Anti-CD19 Chimeric Antigen Receptor T cell))

B-cell Non Hodgkin Lymphoma · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 59Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-cluster of differentiation 19 (CD19, Anti-cluster of differentiation 19, Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells)

Lymphoma, B-Cell; Lymphoma, Non-hodgkins · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 55Status Active
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Preclinical

CD19+CD22 CAR-T (CD19+CD22 CAR-T)

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · CD19

#CD19#CGT#Preclinical#Popular#cell-gene-therapy+5
Trials 53Status Active
CGTLimited DatastaleCRISPR Therapeutics AGPhase 1

CD19-directed CAR-T cells (CD19-directed CAR-T cells)

B-cell Non-Hodgkin Lymphoma · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 53Status Active
CGTLimited DatastaleThe Leukemia and Lymphoma Socie…Phase 1

CD22 CAR (CD22 CAR)

B-ALL; B-cell Non Hodgkin Lymphoma · CD22

#CD22#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 53Status Active
CGTLimited DatastaleJuno Therapeutics, a Subsidiary…Phase 1

JCAR017 (JCAR017, JCAR017 (lisocabtagene maraleucel) 2-dose schedule, lisocabtagene maraleucel)

Non-Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 34Status Active
CGTLimited DatastaleShanghai Unicar-Therapy Bio-med…Phase 1

CD30+ CAR T-cells (CD30+ CAR T-cells)

Classical Hodgkin Lymphoma · CD30

#CD30#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 32Status Recruiting
CGTLimited DatastaleCelgenePhase 3

JCAR017 (JCAR017)

Lymphoma, Non-Hodgkin · Precursor Cell Lymphoblastic Leukemia-Ly

#PrecursorCellLymphoblasticLeukem#CGT#Phase3#cell-gene-therapy#CAR-T+4
Trials 20Status Active
CGTLimited DatastaleShanghai Mingju Biotechnology C…Phase 1

JWCAR029 (JWCAR029)

Non Hodgkin Lymphoma · Non Hodgkin Lymphoma

#NonHodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 14Status Active
CGTLimited DatastaleFundamenta Therapeutics, Ltd.Phase 1

ThisCART19A (ThisCART19A)

Non-Hodgkin's Lymphoma · Allogeneic, CAR-T, Protein Sequestration

#AllogeneicCAR-TProteinSequestrat#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 12Status Recruiting
CGTLimited DatastaleMiltenyi Biotec, Inc.Phase 1

Autologous CAR19 T lymphocytes (Autologous CAR19 T lymphocytes)

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia; Non-Hodgkin's Lymphoma Refractory · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 7Status Recruiting
CGTLimited DatastaleShanghai AbelZeta Ltd.Phase 1

C-CAR011 (C-CAR011)

Refractory or Relapsed Non-Hodgkin Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 6Status Active
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

anti-CD5 CAR T cells (anti-CD5 CAR T cells)

T-cell Acute Lymphoblastic Leukemia; T-cell Non-Hodgkin Lymphoma · T-cell Acute Lymphoblastic Leukemia

#T-cellAcuteLymphoblasticLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 6Status Active
CGTLimited DatastaleGuangdong Ruishun Biotech Co., …Phase 1

CD19-CAR-DNT cells (CD19-CAR-DNT cells)

B-cell Non-Hodgkin's Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 5Status Active
CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

RNA anti-CD19 CAR T cells (RNA anti-CD19 CAR T cells)

Hodgkin Lymphoma With no Available Curative Treatment Options Who Have a Limited Prognosis · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 4Status Discontinued
CGTLimited DatastaleMedical College of WisconsinPhase 1

1.0 x10^5 CAR-20/19-T cells/kg (CAR-20/19-T cells, CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg))

Lymphoma, Non-Hodgkin; Lymphoma, B-Cell · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 1

2.5 x10^5 CAR-20/19-T cells/kg (CAR-20/19-T cells, CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg))

Lymphoma, Non-Hodgkin; Lymphoma, B-Cell · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 1

2.5 x10^6 CAR-20/19-T cells/kg (CAR-20/19-T cells, CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg))

Lymphoma, Non-Hodgkin; Lymphoma, B-Cell · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Active

1 / 6 pages

← PreviousNext →